Michael H. Davidson to Drug Interactions
This is a "connection" page, showing publications Michael H. Davidson has written about Drug Interactions.
Connection Strength
0.387
-
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006 Jan; 5(1):145-56.
Score: 0.066
-
Pharmacokinetic interactions between statins and fibrates. Am J Cardiol. 2005 Nov 07; 96(9A):44K-49K; discussion 34K-35K.
Score: 0.065
-
Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med. 2003 Oct 27; 163(19):2394-5.
Score: 0.057
-
Controversy surrounding the safety of cerivastatin. Expert Opin Drug Saf. 2002 Sep; 1(3):207-12.
Score: 0.052
-
Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions. J Cardiovasc Pharmacol Ther. 2001 Jul; 6(3):219-29.
Score: 0.048
-
No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers. Am J Cardiovasc Drugs. 2017 Jun; 17(3):251-260.
Score: 0.036
-
Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers. J Clin Lipidol. 2017 May - Jun; 11(3):739-748.
Score: 0.036
-
Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003 Mar 10; 163(5):553-64.
Score: 0.014
-
Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation. 2002 Feb 26; 105(8):917-22.
Score: 0.013